Institutions / Decheng Capital LLC

Decheng Capital LLC

CIK 2010850 · Institution · as of Dec 31, 2025

Portfolio value

$743.41M

Positions

As of

Dec 31, 2025

Top holdings

Dec 31, 2025

Company	Class	Value	Shares	% of portfolio
CG Oncology, Inc.	—	$264.55M	6,371,669	35.6%
Nuvation Bio Inc.NUVB	Common Stock	$232.55M	25,954,439	31.3%
Upstream Bio, Inc.UPB	Common Stock	$85.33M	3,143,078	11.5%
Aardvark Therapeutics, Inc.AARD	Common Stock	$51.41M	3,917,299	6.9%
Lyell Immunopharma, Inc.	—	$21.30M	692,050	2.9%
Newamsterdam Pharma Co NV	—	$20.77M	592,057	2.8%
Revolution Medicines, Inc.	—	$15.93M	200,000	2.1%
Arcus Biosciences, Inc.	—	$12.91M	541,559	1.7%
Aclaris Therapeutics, Inc.	—	$12.17M	4,041,736	1.6%
Equillium, Inc.	—	$6.89M	4,447,308	0.9%
BeyondSpring Inc.	—	$6.20M	3,800,702	0.8%
Crinetics Pharmaceuticals, Inc.	—	$4.32M	92,700	0.6%
Krystal Biotech, Inc.	—	$4.27M	17,300	0.6%
Aura Biosciences, Inc.AURA	Common Stock	$1.96M	360,483	0.3%
Zentalis Pharmaceuticals, Inc.ZNTL	Common Stock	$1.79M	1,323,327	0.2%
Pyxis Oncology, Inc.PYXS	Common Stock	$375.8K	326,810	0.1%
4D Molecular Therapeutics, Inc.	—	$332.3K	44,311	0.0%
Nuvation Bio Inc.	—	$213.2K	646,057	0.0%
Rezolute, Inc.	—	$141.4K	59,900	0.0%

Activity

Dec 31, 2025

InsidersInstitutions

This fund's 13F position changes — what it's buying and selling.

No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.